Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Breast Cancer
•
Medical Oncology
•
Breast Cancer, Metastatic
Given possible lack of benefit findings in subset analysis of Monarch 3, would you still use Abemaciclib in a postmenopausal woman with high-risk ER+ breast cancer?
Related Questions
Are there any scenarios you would use CDK 4/6i to treat HR-positive HER2-positive breast cancer in combination with anti-HER2 agents?
What are your top takeaways from SABCS 2023?
In a patient with metastatic HR+/HER2- breast cancer who progressed on adjuvant hormonal therapy, do you start fulvestrant + CDK4/6i or do you wait for NGS testing to determine eligibility for targeted agents such as elacestrant or PIK3CA inhibitors?
What is the current paradigm for breast cancer diagnosed with isolated metastases prior to initial treatment?
What initial treatment would you offer a patient with metastatic triple negative breast cancer with somatic BRCA1/2 mutation, CPS <10?
What are your top takeaways in Breast Cancer from ASTRO 2024?
Do you routinely check echocardiograms on all patients who are starting TDM1?
In what circumstance, if any, would you consider fulvestrant + capivasertib over CDK4/6 inhibitors in a patient who has HR+, PIK3CA mutant metastatic breast cancer?
Is there a correlation with severity of rash as an adverse event and response rate with capivasertib?
Do you offer hormonal therapy in combination with an anti-HER2 T-DM1 or T-DXd in metastatic ER+ HER2+ breast cancer?
